Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression changes in THP1 AML cells following Withaferin A exposure

ABSTRACT: Connectivity map analysis using an AML-specific cMYB gene signature (Walf-Vorderwulbecke et al. Leukemia. 2018;32(4):882-889. 10.1038/leu.2017.317) identified withaferin A (WFA) as a candidate cMYB deregulating agent in AML. In order to validate the predicted effect of WFA on cMYB function, RNAseq analysis was performed on THP1 cells following exposure to DMSO or 1mM WFA for 6 hours.

ORGANISM(S): Homo sapiens

PROVIDER: GSE178940 | GEO | 2022/06/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression changes in THP1 AML cells following Withaferin A exposure

Project description:Gene expression changes in THP1 AML cells following Withaferin A exposure

| PRJNA741523 | ENA

A natural plant derived compound, Withaferin A exploits the stress pathway to induce antitumor immunity

Project description:Analysis of the global effect of plant derived compound Withaferin A on gene expression in rat her-2/neu expressing murine cancer cells at an early time point of 6hrs post treatment. Pathway analyses were performed to determine which metabolic pathways were significantly affected by the Withaferin A.

2014-12-31 | GSE43374 | GEO

Withaferin A (WA) causes cell death in prostate cells.

Project description:Withaferin A (WA), a major chemical component of an Indian herb Withania somnifera, induces cell death (apoptosis/necrosis) in a variety of tumor cells, but its molecular mechanism remains elusive. We report that WA induces cell death selectively in high-grade prostate (PC-3 and DU-145) and tongue (SAS) cancer cells but not in normal human fibroblast (TIG-1) and low-grade prostate cancer (LNCaP) cells. To identify genes whose expression levels were up- or down-regulated in prostate cancer cells following WA treatment, we examined the transcriptome profiles of mRNA prepared from TIG-1, LNCaP, PC-3 and DU-145 cells using Agilent’s Whole Human Genome Microarray.

2015-08-02 | E-GEOD-55728 | biostudies-arrayexpress

Novel cancer-selective and disease subtype-independent mechanistic targets of withaferin A in human breast cancer cells

Project description:We report differential gene expression changes by withaferin A in breast cancer cells versus a normal mammary epithelial cell line.

2020-09-17 | GSE158085 | GEO

Small RNA next genration sequencing of miRNAs in Withaferin A treated MDA-MB-231 cells.

Project description:In this study, we reporte the altered miRNAs expression in the human triple negative breast cancer cell line (MDA-MB-231) in response to withaferin A at IC50 (2 µM) concentration.

2023-01-25 | GSE183395 | GEO

Small RNA next generation sequencing of miRNAs in MCF7 cells derived mammosphere treated with withaferin A

Project description:In this study, we reporte the altered miRNAs expression in the human breast cancer cell line (MCF7) derived mammosphere in response to withaferin A IC50 concentrations (2 µM)..

2024-07-29 | GSE181099 | GEO

Small RNA next genration sequencing of microRNAs in withaferin A treated breast normal epithelial cell line MCF10A

Project description:This study was amied to identify the diffenetiall expressed miRNAs in Withaferin A (WA) treated breast normal cells (MCF10A) in comparision to non-treated cells

2024-07-16 | GSE180247 | GEO

Withaferin A (WA) causes cell death in prostate cells.

2015-08-02 | GSE55728 | GEO

Hypothalamic gene expression profiles from diet-induced obese mice after Celastrol or Withaferin A treatments

Project description:Obesity is characterized by central leptin resistance. Celastrol has been identified to reduce leptin resistance in diet-induced obese and leptin resistant mice. Current microarray data provide the hypothalamic gene expression profiles from mice treated with Celastrol or Withaferin A.

2016-07-08 | GSE84156 | GEO

Transcription profiling of acute monocytic leukemia (AML-M5) patients with DNMT3A mutations

Project description:To understand the pathogenesis of DNMT3A in acute monocytic leukemia (AML-M5), we identified genes that are expressed differently in leukemia cells from AML-M5 patients collected at diagnosis with DNMT3A mutations (6 cases) compared to those without the mutations (4 cases). Differences of expression level were observed in 889 out of 20,723 (4.3%) annotated genes by using Affymetrix microarray with 469 genes upregulated and 420 genes downregulated. Leukemia cells in bone marrow of acute monocytic leukemia patients were collected at diagnosis for RNA extraction and hybridization on Affymetrix microarrays. 6 cases of AML-M5 samples with DNMT3A mutations and 4 cases of AML-M5 samples wihtout DNMT3A mutations were used.

2011-02-12 | E-GEOD-27187 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data